Antibacterial Agents TRIZ Cases

Antisense morpholino oligomers hybridize with bacterial mRNA to inhibit protein expression and restore antibiotic susceptibility.

Recombinant host cells synthesize glucosylated O4 antigen bioconjugates linked to carrier proteins.

Aryl-quinolyl compounds block RAF and RTK activities, inducing apoptosis and addressing excessive angiogenesis in proliferative disorders.

Segmented prime-boost vaccination reduces fecal excretion and systemic colonization of challenge Salmonella strains in avian animals.

Secreted protein from Lactobacillus gasseri HMV18 induces tumor cell apoptosis and inhibits pathogenic bacteria growth.

Furopyridine inhibitors target the BD1 domain to resolve low selectivity in treating inflammatory diseases and cancers.

Citric acid complexes with silver ions to maintain stability at high concentrations, resolving the trade-off between concentration and reliability.

PCR amplification and 16S rDNA sequencing identify specific bacterial signatures in skin samples.

Mild acid and chelating agent solution dismantles biofilm structure to enable safe removal from human tissues without caustic damage.

Substituted quinoline derivatives inhibit bacterial F1F0 ATP synthase to overcome antibiotic resistance in gram-positive and gram-negative strains.

Amido-benzyl sulfone compounds inhibit NAMPT activity to induce apoptotic cell death, addressing limited pharmaceutical properties of existing inhibitors.

Recombinant alpha-1 antitrypsin fused with Fc fragments enables rapid purification via Protein A binding while maintaining therapeutic activity.

Pyridinium hydrogen sulfate enables one-pot synthesis of an imidazole antimicrobial, eliminating volatile organic solvents while maintaining process simplicity.

A topical composition combines cationic antimicrobial peptides with medium molecular weight hyaluronic acid to treat microbial skin infections.

Clomiphene citrate targets undecaprenyl diphosphate synthase to inhibit Mycobacterium abscessus, resolving antibiotic resistance and toxicity issues.

Segmented formulations of cysteamine precursors maintain steady plasma concentrations while minimizing gastrointestinal side effects and peak toxicity.

Humanized antibodies bind specifically to MDL-1, resolving the trade-off between high affinity and interference with other receptors.

Fermentation-derived propionic acid formulations lower bacterial load and side effects from corticosteroids, addressing antibiotic resistance in eczema therapy.

Structural modifications to glycosphingolipids modulate cytokine profiles, reducing toxic effects while maintaining therapeutic effectiveness.

PmpD polypeptide vaccine stimulates protective immunity to reduce Chlamydia trachomatis incidence and severity.

Fusion protein vaccines combine immunogenic polypeptides with adjuvants to overcome serotype replacement risks in pneumococcal protection.

Novel pyrazoloquinolone compounds inhibit the PARP enzyme through specific heterocyclic structures.

Clustered basic residues in modified cathelicidin peptides reduce cytotoxicity while maintaining bactericidal activity against resistant strains.

Fat emulsion with odd-numbered fatty acids prevents critical illness polyneuropathy and myopathy in intensive care patients.

Doppel-targeting antibodies bind specifically to the doppel protein, inhibiting pathological angiogenesis while preserving physiological functions.

Trichoderma enzymes glycosylate flavonoids, resolving low water solubility while maintaining bioavailability.

A plasmid encodes a cI repressor protein to neutralize chromosomal toxins for stable maintenance without antibiotic selection pressure.

S-nitrosylating agents neutralize Clostridium difficile toxins by modifying cysteine residues, resolving inadequate treatment efficacy.

Segmented piperidine-heteroaryl structures target MCP-1 binding pathways, resolving therapeutic effectiveness versus compound complexity.

Peptides mimicking the B7 ligand dimer interface block superantigen binding to T cell receptors, preventing excessive inflammatory cytokine responses.

Tetrahydroquinoline derivatives inhibit factor XIa and plasma kallikrein, reducing adverse effects from non-selective anticoagulants.

Chemical synthesis of phosphorylated heptose compounds using selective hydroxyl protection and sequential phosphorylation.

Merging mutated Stx2A with Stx1B creates a stable fusion protein that neutralizes both toxin types, solving production instability.

A pulmonary vaccine composition uses adjuvants to induce strong systemic and mucosal immune responses through intra-lung delivery.

Novel phenyl-alkyl piperazine compounds inhibit TNF-alpha synthesis through specific structural modifications at defined ring positions.

CDR-grafted humanized antibodies bind interleukin-1alpha with high affinity, neutralizing inflammatory effects in rheumatoid arthritis.

Mutant streptolysin O proteins reduce hemolytic activity to minimize toxicity while retaining immunogenicity for vaccine protection.

Phage display screening isolates monomeric human VH and VL fragments, resolving aggregation issues that limit immunotherapy applications.

Bacteriophage Vib-ANP-1 provides targeted infection to eliminate Vibrio anguillarum without triggering antibiotic resistance or environmental pollution.

Replacing hazardous radiolabels, fluorescent beta-lactam conjugates enable safe, specific, and temporally resolved detection of penicillin-binding proteins.

A one-pot synthesis process yields 2-(homo)piperazine-1,3-benzothiazine-4-one hydrochlorides with high purity.

Quorum sensing antagonists mimic autoinducers to block bacterial communication, preventing antibiotic-resistant biofilm formation.

Pyrazolo pyridine derivatives inhibit NADPH oxidase activity to reduce reactive oxygen species production.

Fluorine and alkyl substitutions block liver microsomal metabolism to extend half-life and plasma exposure of MDM2-p53 inhibitors.

Formula 1 compounds with sulfamoyl and carboxy groups bind class B β-lactamases, reducing minimum inhibitory concentrations against resistant bacteria.

A fiber blend of FOS, acacia gum, and inulin accelerates Clostridium difficile washout while restoring Lactobacilli concentrations.